Skip to main content
Clinical Trials/NCT05285306
NCT05285306
Completed
Not Applicable

Developing and Pilot Testing a Brief Intervention to Reduce Anxiety During Pelvic Examinations Among Female Cancer Survivors (Pelvic Examination and Anxiety Coping Skills for Empowerment: PEACE)

Duke University1 site in 1 country16 target enrollmentMarch 21, 2022
ConditionsAnxiety

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Anxiety
Sponsor
Duke University
Enrollment
16
Locations
1
Primary Endpoint
Intervention feasibility as measured by attrition
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

The purpose of this study is to test the feasibility and acceptability of a brief coping skills training program addressing anxiety and pain related to surveillance pelvic examinations for female gynecologic cancer survivors.

Detailed Description

The investigators have developed and manualized a coping skills training intervention for female gynecologic cancer patients that aims to reduce anxiety related to surveillance pelvic examinations (Pelvic Examination and Anxiety Coping Skills for Empowerment: PEACE). The investigators propose a proof-of concept pilot study to evaluate the acceptability and feasibility of the coping skills intervention. The study will be conducted by Duke University. Participants (N=16) will receive the 3-session telemedicine coping skills intervention. Participants will complete assessments at baseline, post-intervention (within 2 weeks before their next scheduled pelvic examination), and post pelvic examination (2-3 months after the baseline assessment). Study aims are: Aim 1) Assess intervention acceptability and feasibility through quantitative measurement and qualitative feedback from semi-structured interviews, and Aim 2) Graphically depict patterns of change in outcome variables and intervention targets.

Registry
clinicaltrials.gov
Start Date
March 21, 2022
End Date
September 2, 2022
Last Updated
2 years ago
Study Type
Interventional
Study Design
Single Group
Sex
Female

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • female sex
  • diagnosis of stage I-IV cervical or endometrial cancer
  • 18 years of age or older
  • able to speak/read English
  • able to give informed consent
  • completed cancer treatments within 2-24 months prior to enrollment, and recommended to undergo surveillance pelvic examination at three month intervals
  • able to commit to three 45-60 minute visits within the study period
  • able to participate in the intervention via the telemedicine modality (e.g., phone or video)

Exclusion Criteria

  • unable to provide informed consent
  • major untreated or uncontrolled mental illness
  • hearing impairment that impedes telephone or video calls

Outcomes

Primary Outcomes

Intervention feasibility as measured by attrition

Time Frame: post pelvic examination (approximately 2-3 months after baseline)

Retention logs will capture the number of participants who did not complete the study protocol (rate of attrition)

Intervention feasibility as measured by survey completion

Time Frame: post pelvic examination (approximately 2-3 months after baseline)

Retention logs will capture the number of participants who completed all assessments

Intervention acceptability will be assessed using an adapted version of the Satisfaction with Therapy and Therapist Scale (STTS-R)

Time Frame: post pelvic examination (approximately 2-3 months after baseline)

The adapted STTS-R consists of 18 items that assess satisfaction with the therapist and the intervention on a 5-point Likert-type scale from 1 (strongly disagree) to 5 (strongly agree).

Change in intervention acceptability will be assessed using an adapted version of the Satisfaction with Therapy and Therapist Scale (STTS-R)

Time Frame: post-intervention (within 2 weeks of their next pelvic examination), post pelvic examination (approximately 2-3 months after baseline)

Change in intervention acceptability from immediately after completion of the 3 sessions (post intervention assessment) to after trying to implement the coping skills during their next pelvic examination (post pelvic exam assessment), using the STTS-R. The adapted STTS-R consists of 18 items that assess satisfaction with the therapist and the intervention on a 5-point Likert-type scale from 1 (strongly disagree) to 5 (strongly agree).

Intervention feasibility as measured by percentage of recruited participants who enrolled

Time Frame: post pelvic examination (approximately 2-3 months after baseline)

Enrollment logs will capture the number of participants who were recruited and among them, the number that enrolled in the study.

Intervention feasibility as measured by home practice completion

Time Frame: post-intervention (within 2 weeks of their next pelvic examination)

Interventionist logs completed at the conclusion of each session will capture the level of home practice completion

Intervention feasibility as measured by participant engagement

Time Frame: post-intervention (within 2 weeks of their next pelvic examination)

Interventionist logs completed at the conclusion of each session will capture the level of participant engagement with a 1 item question rated from 1 (not at all engaged) to 4 (highly engaged).

Intervention feasibility as measured by interventionist fidelity

Time Frame: post-intervention (within 2 weeks of their next pelvic examination)

Fidelity rating forms will be used to measure the level of fidelity to session content for one third of the sessions for the protocol. Each component of the session will be rated from 0 (not covered at all) to 3 (thoroughly covered the topic)

Secondary Outcomes

  • Change in anxiety related to examination as measured by the The State Anxiety Scale of the State-Trait Anxiety Inventory(baseline, post-intervention (within 2 weeks of their next pelvic examination), post pelvic examination (approximately 2-3 months after baseline))
  • Change in pain during examination as measured by numeric scales(baseline, post pelvic examination (approximately 2-3 months after baseline))

Study Sites (1)

Loading locations...

Similar Trials